Lupus Nephritis - Pipeline Review, H1 2012

Lupus Nephritis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Lupus Nephritis - Pipeline Review, H1 2012', provides an overview of the Lupus Nephritis therapeutic pipeline. This report provides information on the therapeutic development for Lupus Nephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lupus Nephritis. 'Lupus Nephritis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lupus Nephritis.
- A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lupus Nephritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Lupus Nephritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Lupus Nephritis Therapeutic Products under Development, Key Players in Lupus Nephritis Therapeutics, Lupus Nephritis Pipeline Overview, Lupus Nephritis Pipeline, Lupus Nephritis Pipeline Assessment SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lupus Nephritis Overview
Therapeutics Development
An Overview of Pipeline Products for Lupus Nephritis
Lupus Nephritis Therapeutics under Development by Companies
Lupus Nephritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Lupus Nephritis Therapeutics – Products under Development by Companies
Lupus Nephritis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Lupus Nephritis Therapeutics Development
Bristol-Myers Squibb Company
Biogen Idec Inc.
Genentech, Inc.
Novartis AG
Teva Pharmaceutical Industries Limited
Deciphera Pharmaceuticals, LLC
NOXXON Pharma AG
NasVax Ltd.
Lupus Nephritis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Laquinimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-TWEAK - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Orencia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOX-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOX-E36 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclosporine A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycophenolate Mofetil + Prednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Corticosteroids + Methylprednisolone + Mycophenolate mofetil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycophenolate Sodium + Corticosteroids - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Myfortic - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abatacept + Cyclophosphamide + Azathioprine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycophenolate Mofetil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamibarotene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Advagraf - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-aCD3 Mab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclosporine + Mycophenolic Acid + Prednison - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-5599 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cFMS Kinase Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lupus Nephritis Therapeutics – Drug Profile Updates
Lupus Nephritis Therapeutics – Discontinued Products
Lupus Nephritis Therapeutics - Dormant Products
Lupus Nephritis – Product Development Milestones
Featured News & Press Releases
Jun 03, 2010: CellCept Reached Positive Results In Phase III Trial In Lupus Nephritis
Jun 27, 2007: Preliminary Results For Phase III Study Evaluating CellCept In Lupus Nephritis.
Jan 26, 2007: Approval of Prograf for Lupus Nephritis in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Lupus Nephritis, H1 2012
Products under Development for Lupus Nephritis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Bristol-Myers Squibb Company, H1 2012
Biogen Idec Inc., H1 2012
Genentech, Inc., H1 2012
Novartis AG, H1 2012
Teva Pharmaceutical Industries Limited, H1 2012
Deciphera Pharmaceuticals, LLC, H1 2012
NOXXON Pharma AG, H1 2012
NasVax Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Lupus Nephritis Therapeutics – Drug Profile Updates
Lupus Nephritis Therapeutics – Discontinued Products
Lupus Nephritis Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Lupus Nephritis, H1 2012
Products under Development for Lupus Nephritis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012